Entera Bio (NASDAQ:ENTX) Posts Earnings Results, Beats Estimates By $0.02 EPS

Entera Bio (NASDAQ:ENTX) released its quarterly earnings results on Friday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.02, Zacks reports. Entera Bio had a negative return on equity of 77.75% and a negative net margin of 4,525.11%.

Entera Bio Stock Down 1.1%

Shares of ENTX traded down $0.03 during mid-day trading on Friday, hitting $2.71. The company had a trading volume of 49,405 shares, compared to its average volume of 257,239. Entera Bio has a 1-year low of $1.50 and a 1-year high of $3.22. The business’s 50-day simple moving average is $2.29 and its 200-day simple moving average is $2.09. The stock has a market cap of $123.75 million, a PE ratio of -10.42 and a beta of 1.67.

Wall Street Analyst Weigh In

ENTX has been the subject of a number of research reports. HC Wainwright upgraded shares of Entera Bio to a “strong-buy” rating in a research report on Monday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $10.00.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.